The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the ...

Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi, has announced that the National Institute for Health and ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without ...

Researchers said a better understanding of barriers to bone health in hemophilia and VWD is needed, and guidelines should be ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The findings showed that fitusiran lowers antithrombin levels to enhance thrombin generation and restore hemostasis in ...

The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

When Jessamyn Butler would get nosebleeds as a child, her mother would tell her the length of the bleed was normal, no matter ...